Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
65.00
Dollar change
+1.42
Percentage change
2.23
%
Index- P/E- EPS (ttm)-1.14 Insider Own2.33% Shs Outstand49.73M Perf Week5.03%
Market Cap3.23B Forward P/E- EPS next Y-2.34 Insider Trans-9.69% Shs Float48.57M Perf Month-6.08%
Income-55.40M PEG- EPS next Q-0.36 Inst Own74.13% Short Float8.84% Perf Quarter-6.47%
Sales249.84M P/S12.94 EPS this Y-45.16% Inst Trans23.06% Short Ratio8.82 Perf Half Y28.28%
Book/sh7.37 P/B8.81 EPS next Y-42.68% ROA-9.89% Short Interest4.29M Perf Year40.94%
Cash/sh8.90 P/C7.30 EPS next 5Y- ROE-15.74% 52W Range42.21 - 76.98 Perf YTD-4.86%
Dividend Est.- P/FCF- EPS past 5Y- ROI-12.27% 52W High-15.56% Beta0.89
Dividend TTM- Quick Ratio3.77 Sales past 5Y88.61% Gross Margin99.46% 52W Low53.99% ATR (14)2.42
Dividend Ex-Date- Current Ratio3.80 EPS Y/Y TTM-0.80% Oper. Margin-23.66% RSI (14)52.03 Volatility3.45% 3.95%
Employees497 Debt/Eq0.23 Sales Y/Y TTM42.70% Profit Margin-22.17% Recom1.29 Target Price84.44
Option/ShortYes / Yes LT Debt/Eq0.22 EPS Q/Q34.63% Payout- Rel Volume0.74 Prev Close63.58
Sales Surprise5.37% EPS Surprise-61.42% Sales Q/Q25.54% EarningsFeb 28 BMO Avg Volume486.68K Price65.00
SMA203.44% SMA50-4.67% SMA2008.86% Trades Volume357,997 Change2.23%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Resumed JP Morgan Overweight $60
Nov-02-23Initiated Cantor Fitzgerald Overweight
Oct-31-23Initiated Robert W. Baird Outperform $84
Sep-13-23Upgrade JP Morgan Neutral → Overweight $9 → $22
Sep-13-23Initiated Needham Buy $75
Aug-16-23Initiated CapitalOne Overweight $84
Jul-17-23Initiated Canaccord Genuity Hold $67
Mar-31-23Initiated Mizuho Buy $70
Mar-30-23Initiated Guggenheim Buy $85
Mar-24-23Initiated Bryan Garnier Buy $16
Mar-13-24 11:07AM
Mar-05-24 04:30PM
Mar-01-24 07:00AM
Feb-29-24 10:51AM
Feb-28-24 04:53PM
07:34AM Loading…
07:34AM
Feb-22-24 07:00AM
Feb-21-24 07:00AM
Feb-01-24 09:00AM
05:16AM
Jan-30-24 11:30PM
Jan-29-24 04:05PM
Jan-10-24 09:55AM
Jan-09-24 01:51PM
Jan-05-24 07:00AM
07:00AM Loading…
Jan-03-24 07:00AM
Dec-18-23 12:00PM
Dec-13-23 09:55AM
Nov-30-23 04:00AM
Nov-27-23 09:55AM
Nov-20-23 09:55AM
Nov-14-23 09:09AM
Nov-10-23 09:55AM
Nov-07-23 07:00AM
Nov-01-23 04:01PM
Oct-30-23 04:30PM
Oct-21-23 08:45AM
Oct-19-23 09:55AM
Oct-07-23 03:33PM
Oct-06-23 07:01AM
06:40PM Loading…
Sep-22-23 06:40PM
Sep-14-23 02:02PM
Sep-11-23 05:00PM
Sep-01-23 04:00PM
Aug-13-23 07:15AM
Aug-10-23 10:22PM
07:00AM
Aug-08-23 08:48AM
Aug-03-23 08:00AM
Jul-18-23 06:05AM
Jun-07-23 06:59AM
Jun-03-23 07:00AM
Jun-01-23 04:30PM
May-17-23 01:18AM
May-11-23 06:00AM
May-10-23 07:00AM
May-03-23 04:30PM
Apr-24-23 01:00AM
Apr-19-23 12:00AM
Apr-18-23 07:00AM
07:00AM
Apr-17-23 08:32AM
Apr-11-23 07:00AM
Apr-05-23 06:00PM
Mar-30-23 06:00PM
09:00AM
Mar-28-23 03:57PM
Mar-24-23 06:00PM
Mar-16-23 06:00PM
09:00AM
Mar-14-23 04:30PM
Mar-03-23 10:55AM
Mar-01-23 11:32PM
07:00AM
Feb-28-23 08:30AM
07:00AM
Feb-27-23 01:47PM
Feb-24-23 09:00AM
Feb-23-23 07:00AM
Feb-22-23 05:50PM
01:32PM
07:00AM
Feb-15-23 05:50PM
Feb-14-23 06:57AM
05:40AM
Feb-13-23 05:35PM
Feb-08-23 05:50PM
Feb-03-23 02:58PM
Feb-02-23 05:50PM
Feb-01-23 09:00AM
07:00AM
Jan-30-23 10:20AM
Jan-27-23 05:50PM
Jan-25-23 06:00PM
Jan-20-23 01:34PM
Jan-19-23 06:00PM
09:40AM
Jan-18-23 06:50AM
Jan-13-23 04:41AM
Jan-11-23 08:02AM
Jan-09-23 07:00AM
Jan-06-23 06:35PM
Jan-04-23 07:00AM
Dec-30-22 10:00AM
Dec-28-22 07:15AM
Dec-27-22 11:21AM
Dec-22-22 10:53AM
06:22AM
Dec-21-22 09:51AM
Dec-20-22 09:06AM
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Berman David MHEAD OF R&DFeb 28 '24Option Exercise17.4636,509637,44736,509Mar 01 04:15 PM
Berman David MHEAD OF R&DFeb 28 '24Sale68.5936,5092,504,1580Mar 01 04:15 PM
Berman David MHEAD OF R&DFeb 27 '24Option Exercise17.4654,938959,21754,938Feb 28 04:15 PM
Berman David MHEAD OF R&DFeb 27 '24Sale70.8654,9383,893,0300Feb 28 04:15 PM
Berman David MHEAD OF R&DFeb 26 '24Option Exercise17.4628,553498,53528,553Feb 28 04:15 PM
Berman David MHEAD OF R&DFeb 26 '24Sale70.6528,5532,017,2880Feb 28 04:15 PM
St Leger Tina AmberChief HR OfficerJan 03 '24Option Exercise29.874,375130,6814,375Jan 05 04:17 PM
St Leger Tina AmberChief HR OfficerJan 03 '24Sale69.894,375305,7810Jan 05 04:17 PM